INZOLAM 0.25MG TABLET

Страна: Малайзія

мова: англійська

Джерело: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Активний інгредієнт:

TRIAZOLAM

Доступна з:

DUOPHARMA (M) SDN. BHD.

ІПН (Міжнародна Ім'я):

TRIAZOLAM

Одиниць в упаковці:

100Tablet Tablets; 500Tablet Tablets

Виробник:

DUOPHARMA (M) SDN. BHD.

інформаційний буклет

_Consumer Medication Information Leaflet (RIMUP) _
1
INZOLAM TABLET
Triazolam 0.25mg
WHAT IS IN THE LEAFLET?
1.
What
INZOLAM
is
used
for
2.
How INZOLAM works
3.
Before you use INZOLAM
4.
How to use INZOLAM
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
INZOLAM
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of Revision
WHAT INZOLAM IS USED FOR
Inzolam
is
used
to
treat
sleeping problems, also called
insomnia. It should be used for
short-term treatment only.
Continuous
long-term
use
is
not
recommended
unless
advised
by
your
doctor.
The
use
of
benzodiazepines
may
lead
to
dependence
on
the
medicine.
Your
doctor,
however,
may
have prescribed this medicine
for another reason.
Ask your doctor if you have
questions
about
why
it
has
been prescribed for you.
HOW INZOLAM WORKS
Inzolam belongs to a group of
medicines
called
short-acting
benzodiazepines.
They
are
thought to work by their action
on brain chemicals.
BEFORE YOU USE INZOLAM
_When you must not take it _
Do not take Inzolam if you:

have
an
allergy
to
triazolam,
any
other
benzodiazepine, or any of
the ingredients listed at the
end of this leaflet.

some
symptoms
of
an
allergic
reaction
include
skin
rash,
itching,
shortness
of
breath
or
swelling of the face, lips
or
tongue,
which
may
cause
difficulty
in
swallowing or breathing.

are
suffering
from
depression
or
are
taking
nefazodone,
a
medicine
used
for
treating
depression.

are
taking
medicines
to
treat
fungal
infections
(ketoconazole
and
itraconazole).

have
severe
and
chronic
lung disease.

suffer from a disease that
causes
severe
muscle
weakness
known
as
myasthenia gravis.

are
pregnant
or
plan
to
become pregnant. Do not
use in future episodes of
insomnia
unless
you
are
sure you are not pregnant.

are
breastfeeding
or
plan
to breast-feed.
Do not take it after the expiry
date printed on the pack.
If you take it after the expiry
date
has
passed,
it
may
not
work as well.
Do not take it if the packaging
is
torn
or
shows
signs
of
tampering.

Характеристики продукта

[DUOPHARMA (M) SDN BHD]
Page 1 of 2
[REVISION DATE: 12.06.2019]
INZOLAM TABLET 0.25 MG
DESCRIPTION:
An oval, scored tablet blue in colour with markings ‘DUO 861’ and
‘d/d’.
COMPOSITION:
Each tablet contains Triazolam 0.25mg.
PHARMACODYNAMICS:
Triazolam is a potent short-acting benzodiazepines with general
properties similar to those of diazepam.
PHARMACOKINETICS:
Triazolam is rapidly and nearly completely absorbed from the
gastrointestinal tract, peak plasma concentrations being achieved
within 2 hours of administration by mouth. Triazolam has a plasma
elimination half-life ranging from 1.5 to 5.5 hours. It is reported to
be about 89% bound to plasma proteins. Hydroxylation of Triazolam in
the liver is mediated by the cytochrome P450 isozyme CYP3A4.
Triazolam is excreted in the urine mainly in the form of its
conjugated metabolites with only small amounts appearing unchanged.
INDICATION:
Inzolam is useful in the management of patients with transient and
short term insomnia. It is also useful as a short term adjunctive
treatment in the management of selected patients with long-term
insomnia.
RECOMMENDED DOSAGE:
It is important to individualized dosage of Triazolam in patients
within various population groups in order to obtain maximum
therapeutic effect while using the smallest effective dose. The
recommended
dose for most adults is 0.25 mg before retiring. A dose of 0.125 mg
may be found sufficient for some patients (e.g. low body weight). A
dose of 0.5 mg should be used only for exceptional patients who do
not respond adequately to a trial of a lower dose since the risk of
several adverse reactions increases with the size of the dose
administered.
A dose of 0.5mg should not be exceeded. In geriatric and/or
debilitated patients the recommended dosage range is 0.125 mg to 0.25
mg.
Therapy should be initiated at 0.125 mg in this group and the 0.25 mg
dose should be used only for exceptional patients who do not respond
to a trial of the lower dose. A total dose of 0.25 mg should not
be exceeded in these pati